World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
31126
World Ranking
15451
National Ranking
1421

Nick Thatcher publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nick Thatcher sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 551 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nick Thatcher D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nick Thatcher sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nick Thatcher is affiliated with the University of Manchester in the United Kingdom. Their academic and professional activities are connected to this institution.

The available data does not include specific details about their recent publications, co-authors, frequent publication venues, or their contributions to book publications. Additionally, no information regarding their main fields of study, subfields, or specific research topics is recorded.

There are no recorded awards associated with Nick Thatcher. The data does not indicate any honors or recognitions granted over the course of their career.

As no information about publications is provided, summative lists of papers, including titles, years, and venues, cannot be offered.

Best Publications

  • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

    Nick Thatcher;Alex Chang;Purvish Parikh;José Rodrigues Pereira

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

    Fred R. Hirsch;Marileila Varella-Garcia;Paul A. Bunn;Wilbur A. Franklin

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

    M. H. Bronchud;J. H. Scarffe;N. Thatcher;D. Crowther

  • Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

    Sarah Burdett;S. Burdett;R. Stephens;L. Stewart

  • Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

    Mary E.R. O'Brien;Tudor-Eliade Ciuleanu;Hristo Tsekov;Yaroslav Shparyk

  • Alternate splicing produces a novel cyclin D1 transcript.

    D. C. Betticher;N. Thatcher;H. J. Altermatt;P. Hoban

  • Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Charles Butts;Mark A Socinski;Paul L R Mitchell;Nick Thatcher

  • Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

    Heather Anderson;B Lund;F Bach;Nick Thatcher

  • Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

    Heather Anderson;Penelope Hopwood;R J Stephens;Nick Thatcher

  • Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study

    Sanjiv S. Agarwala;John M. Kirkwood;Martin Gore;Brigitte Dreno

  • Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer

    Malcolm R Ranson;Neville Davidson;Marianne Nicolson;Stephen J Falk

  • Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

    T Le Chevalier;G Scagliotti;R Natale;S Danson

  • Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

    Nick Thatcher;Fred R Hirsch;Alexander V Luft;Aleksandra Szczesna

  • Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

    N M Bleehen;E S Newlands;Siow Ming Lee;Nick Thatcher

  • Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

    Lucio Crinò;Eric Dansin;Pilar Garrido;Frank Griesinger

  • Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.

    D. C. Betticher;J. Heighway;P. S. Hasleton;H. J. Altermatt

  • Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

    Barry W Hancock;Keith Wheatley;S Harris;Natalie J Ives

  • Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.

    Alex Chang;Purvish Parikh;Sumitra Thongprasert;Eng Huat Tan

Frequent Co-Authors

Paul Lorigan
Paul Lorigan University of Manchester
Fiona H Blackhall
Fiona H Blackhall University of Manchester
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Geoffrey P. Margison
Geoffrey P. Margison University of Manchester
John Radford
John Radford University of Manchester
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Mark R. Middleton
Mark R. Middleton University of Oxford
Corey J. Langer
Corey J. Langer University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers but seeking alternative routes to a traditional MD program, there are several online degrees and certifications worth considering. Online ADN programs allow students to pursue an Associate Degree in Nursing from the comfort of home, making it easier for working professionals or those with family commitments to enter nursing.

Administrative healthcare roles are also growing in demand. If managing hospital operations or patient records appeals to you, a healthcare administration online degree can offer flexible coursework and a quick pathway into the field.

Medical billing and coding is another rewarding career with plentiful opportunities. Many online medical billing and coding schools that accept fafsa exist for those needing financial assistance.

For aspiring practical nurses, some schools do not require the traditional pre-admission tests. If you're wondering, do you have to take a teas test for lpn, it's worth exploring schools with less stringent entrance exams to accelerate your entry into the field.

Best Scientists Citing Nick Thatcher

Trending Scientists

Recently Published Articles